Industry News: Longer interval between Pfizer vaccine doses boosts immunity
Researchers found that longer dosing intervals led to higher antibody levels and a higher proportion of ‘helper’ T cells
23 Jul 2021
One of the world’s most in-depth studies into COVID-19 immune response to vaccines shows both short and long dosing schedules of the Pfizer COVID-19 vaccine generate strong antibody and T cell immune responses.
The new preprint study involving University of Liverpool researchers found that after two doses, the longer dosing interval led to higher antibody levels and a higher proportion of ‘helper’ T cells, which support immune memory and antibody response.